Gene Linked to Dementia and Cancer Risks

Researchers at the University of Kentucky Sanders-Brown Center on Aging have identified a genetic variant that appears to alter the risk of dementia and cancer in opposing directions, according to a study published in *Nature Communications*. The discovery, based on an analysis of over 1 million genetic samples, suggests that a specific mutation in the *APOE* gene—known for its role in Alzheimer’s disease—is linked to a heightened risk of dementia but a reduced likelihood of developing cancer. Conversely, variations in the *TP53* gene, a key tumor suppressor, were associated with lower cancer risk yet increased susceptibility to neurodegenerative conditions.

The study, which combined genome-wide association data with functional experiments in cellular models, revealed that these genetic interactions may stem from shared biological pathways regulating inflammation, DNA repair, and cellular aging. For instance, the *APOE ε4* allele, a well-established risk factor for Alzheimer’s, was found to dampen immune responses that could otherwise combat cancerous cells, while *TP53* mutations may accelerate neuronal decline. Researchers emphasized that the findings do not imply causation but highlight complex trade-offs in the body’s molecular defenses. They also noted that environmental and lifestyle factors likely modulate these genetic effects, which vary across populations.

The results underscore the interconnected nature of age-related diseases and could inform future strategies for personalized medicine. By understanding how genetic variants shape disease risk profiles, scientists hope to develop therapies that target common mechanisms, potentially reducing the burden of both dementia and cancer. The team plans to expand their research to explore additional genetic links and validate these findings in diverse demographic groups.